BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20026273)

  • 1. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
    Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
    Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
    Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
    Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
    Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
    J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Base excision repair as a therapeutic target in colon cancer.
    Liu L; Nakatsuru Y; Gerson SL
    Clin Cancer Res; 2002 Sep; 8(9):2985-91. PubMed ID: 12231545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
    Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
    Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
    Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
    J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
    Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
    Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
    Reese JS; Davis BM; Liu L; Gerson SL
    Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
    Chen TC; Cho HY; Wang W; Nguyen J; Jhaveri N; Rosenstein-Sisson R; Hofman FM; Schönthal AH
    Cancer Lett; 2015 Mar; 358(2):144-151. PubMed ID: 25524552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
    Turriziani M; Caporaso P; Bonmassar L; Buccisano F; Amadori S; Venditti A; Cantonetti M; D'Atri S; Bonmassar E
    Pharmacol Res; 2006 Apr; 53(4):317-23. PubMed ID: 16412662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
    Caporali S; Alvino E; Levati L; Esposito AI; Ciomei M; Brasca MG; Del Bufalo D; Desideri M; Bonmassar E; Pfeffer U; D'Atri S
    Biochem Pharmacol; 2012 Sep; 84(5):598-611. PubMed ID: 22704958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
    Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
    Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
    Tentori L; Dorio AS; Mazzon E; Muzi A; Sau A; Cuzzocrea S; Vernole P; Federici G; Caccuri AM; Graziani G
    Eur J Cancer; 2011 May; 47(8):1219-30. PubMed ID: 21269821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.